Chargement en cours...
NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations
Misregulation of hedgehog (Hh) signaling has been implicated in the pathogenesis of basal cell carcinoma (BCC) and medulloblastoma. Vismodegib, an orally bioavailable Hh signal pathway inhibitor targeting Smo, has been approved for the treatment of advanced BCC. However, acquired drug resistance to...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Blackwell Publishing Ltd
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4186412/ https://ncbi.nlm.nih.gov/pubmed/25505589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.43 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|